UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 2 9, 2026

Metavia inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-37809	47-2389984
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

545 Concord Avenue, Suite 210 Cambridge, Massachusetts (Address of principal executive offices)		02138 (Zip Code)

(857) 702-9600

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MTVA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

On July 9, 2026, MetaVia Inc. (the “Company”) issued a press release announcing that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity (the “Phase 1 Trial”) have successfully completed dose titration and are now receiving their highest target doses in both study cohorts, and that topline data from the Phase 1 Trial is on track to be released in the fourth quarter of 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference.

Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.

The information in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 8.01

Other Events.

On ~~November 6~~July 9, ~~2025~~2026, ~~MetaVia Inc. (~~the “ Company”) ~~entered~~provided ~~into~~ an update Aton ~~The~~its ~~Market~~ongoing ~~Offering~~Part 3 ~~Agreement~~of ~~(the~~its ~~“Sales~~Phase ~~Agreement”)~~1 ~~with~~clinical ~~Ladenburg Thalmann~~trial &evaluating ~~Co.~~DA-1726 ~~Inc.,~~for asthe ~~sales~~treatment ~~agent~~of ~~and/or principal (“Ladenburg”)~~obesity, ~~pursuant~~reporting tothat ~~which~~all ~~the Company may offer and sell,~~enrolled ~~from~~active ~~time~~patients toin ~~time~~the ~~through~~trial orhave tosuccessfully ~~Ladenburg,~~completed ~~shares~~dose oftitration ~~the~~and ~~Company’s~~are ~~common~~now ~~stock,~~receiving ~~par~~their ~~value~~highest ~~$0.001,~~target bydoses ~~any~~of ~~method~~48 ~~permitted~~mg ~~by law~~and ~~deemed~~64 tomg ~~be an “at the market offering” as defined~~ in ~~Rule~~both ~~415(a)(4)~~study ~~of the U~~cohorts.S. ~~Securities~~The ~~Act of 1933, as amended. On July 2, 2026, the~~ Company ~~filed~~is astill ~~prospectus~~planning ~~supplement~~to ~~with~~release the ~~Securities~~data ~~and~~readout ~~Exchange Commission~~ for ~~the~~Part 3 ~~offer~~of ~~and~~its ~~sale~~Phase of1 upclinical totrial ~~$4,000,000~~evaluating ofDA-1726 ~~shares~~in ~~of common stock pursuant to~~ the ~~Sales~~fourth ~~Agreement~~quarter ~~(the~~of ~~“Prospectus Supplement”)~~2026.

Honigman LLP, counsel to the Company, has issued an opinion regarding the validity of the shares of common stock to be issued and sold pursuant to the Sales Agreement and the Prospectus Supplement. A copy of the opinion is filed as Exhibit 5.1 to this Current Report on Form 8Forward-K.Looking Statements

This ~~Current~~ Report, onincluding Exhibit ~~Form 8-K shall~~99.1 attached ~~not~~hereto, ~~constitute~~contains anforward-looking statements ~~offer~~within tothe ~~sell~~meaning orof athe ~~solicitation~~federal ofsecurities anlaws. ~~offer~~These forward-looking statements are tobased ~~buy~~on ~~any~~current ~~securities,~~expectations ~~nor~~and ~~shall~~are ~~there~~not beguarantees ~~any~~of ~~sale~~future ofperformance. ~~these~~Further, ~~securities~~the forward-looking statements inare ~~any~~subject ~~state~~to orthe ~~jurisdiction~~limitations listed in ~~which~~Exhibit 99.1 ~~such~~and anin ~~offer,~~the ~~solicitation~~other orreports ~~sale~~that ~~would~~the beCompany ~~unlawful~~has ~~prior~~filed towith ~~registration~~the orSecurities ~~qualification~~and ~~under~~Exchange ~~the~~Commission, ~~securities~~including ~~laws~~that ofactual ~~any~~events ~~such~~or ~~state~~results ormay ~~other~~differ ~~jurisdiction~~materially from those in the forward-looking statements.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
5.1		Opinion of Honigman LLP.
99.1		Press Release dated July 9, 2026.
104		Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MetaVia Inc.
	MetaVia Inc.

Date: July 9, 2026	By:	/s/ Hyung Heon Kim
Date: July 2, 2026	By:	/s/ Hyung Heon Kim
		Hyung Heon Kim
		Hyung Heon Kim
		President and Chief Executive Officer
		President and Chief Executive Officer

Filing Compare · MetaVia Inc.